Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
SAN DIEGO and TORONTO, March 02, 2017 -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of patients with life-threatening hematologic cancers, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the upcoming conferences:
| • Cowen and Company 37th Annual Healthcare Conference | |
| Time: | 8:40 a.m. ET |
| Date: | Wednesday, March 8, 2017 |
| Location: | Boston, MA |
| Live webcast: | |
| http://wsw.com/webcast/cowen38/apto | |
| • 29th Annual ROTH Conference | |
| Time: | 12:00 p.m. PT |
| Date: | Tuesday, March 14, 2017 |
| Location: | Laguna Niguel, CA |
| Live webcast: | |
| http://wsw.com/webcast/roth31/apto | |
The audio webcasts can also be accessed through the Aptose website at www.aptose.com and will be archived shortly after the live event and available for 90 days.
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing first-in-class agents directed against fundamental drug targets at the leading edge of cancer research. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.
For further information, please contact: Aptose Biosciences Greg Chow, CFO 647-479-9825 [email protected] SMP Communications Susan Pietropaolo 201-923-2049 [email protected]
